[Therapy and prognosis in Ewing's sarcoma].
The results of treatment of 134 cases of morphologically-verified localized Ewing's sarcoma were evaluated. A comparative analysis showed relapse-free survival to be significantly lower for radiation treatment (23%) than for its combination with various cytostatic drugs. Two-year relapse-free survival rate was as high as 43% in cases receiving sarcolysin or cyclophosphamide as adjuvants. This was matched by 47% for adjuvant adriamycin or carminomycin and 56% for adriamycin plus cyclophosphamide and vincristine. Evaluation of long-term results of adjuvant chemotherapy showed sex, age and site of involvement to be of certain prognostic value.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide
Terapiia i prognoz pri sarkome Iuinga.